Who Owns Apellis Pharmaceuticals Company?

Apellis Pharmaceuticals Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Apellis Pharmaceuticals?

Understanding a company's ownership is key for investors. Apellis Pharmaceuticals went public in November 2017, raising about $150 million. This IPO marked a significant shift, moving the company from private to public ownership.

Founded in 2009, Apellis Pharmaceuticals, Inc. focuses on developing treatments for complement-driven diseases. The company's work targets the immune system's complement system to address severe conditions, including those treated by Apellis Pharmaceuticals PESTEL Analysis.

As of August 2025, Apellis has a market cap of around $3.37 billion. In 2024, the company reported $471.3 million in revenue but a net loss of $717.4 million. For Q2 2025, revenues were $178.5 million with a net loss of $42.2 million.

Apellis Pharmaceuticals, Inc. was established in 2009 by a trio of co-founders: Cedric Francois, M.D., Ph.D., Pascal Deschatelets, Ph.D., and Alec Machiels, JD, MBA. Dr. Francois, with his background in medicine and transplantation research, leads the company as CEO and President. Dr. Deschatelets serves as Chief Scientific Officer, while Mr. Machiels also contributes as a co-founder and board member. This foundational team set the company's strategic direction, focusing on addressing unmet medical needs in complement-driven diseases.

Founding Year

Apellis Pharmaceuticals was co-founded in 2009. This marked the beginning of its journey to develop treatments for complement-driven diseases.

Initial Financing

In its early stages in 2009, Apellis secured $32.5 million in Series A financing. This funding was crucial for advancing its scientific objectives.

Early Investors

Key early backers included Vatera Healthcare Partners and Morningside Capital. These investors provided the initial capital to support the company's growth.

Morningside's Stake

As of 2025, Morningside Venture Investments Ltd remains a significant shareholder. They hold 10.14% of the company's shares, indicating a continued strong interest.

Founders' Vision

The founding team's vision was to address unmet medical needs in complement-driven diseases. This focus has guided the company's strategic direction and development pipeline.

Public Disclosure

Detailed equity splits or specific shareholdings at the company's inception are not publicly disclosed. Information on early ownership agreements is also not readily available.

The early ownership structure of Apellis Pharmaceuticals was shaped by its founding team and initial investors. While precise details of equity distribution at the company's inception are not publicly available, the significant early investment from Vatera Healthcare Partners and Morningside Capital was instrumental in launching the company's operations. The continued substantial stake held by Morningside Venture Investments Ltd as of 2025 underscores the long-term commitment of early backers. Understanding the Growth Strategy of Apellis Pharmaceuticals is key to appreciating how this initial ownership structure has evolved to support the company's mission.

Key Aspects of Early Ownership

The initial phase of Apellis Pharmaceuticals was characterized by strategic fundraising and the establishment of its core leadership. The founders' expertise and vision were central to attracting early investment and setting the company's scientific trajectory.

• Founding in 2009 by Cedric Francois, Pascal Deschatelets, and Alec Machiels.
• Secured $32.5 million in Series A financing during its initial phase.
• Early investment from Vatera Healthcare Partners and Morningside Capital.
• Morningside Venture Investments Ltd held 10.14% of shares as of 2025.
• Focus on addressing complement-driven diseases was the core vision.

Apellis Pharmaceuticals SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Apellis Pharmaceuticals became a publicly traded entity following its Initial Public Offering (IPO) on November 9, 2017. This event successfully raised approximately $150 million through the sale of 10,714,000 shares at $14.00 per share. The company's market capitalization has seen substantial growth since its IPO, reaching an estimated $3.37 billion USD by August 2025.

The ownership landscape of Apellis Pharmaceuticals is predominantly shaped by institutional investors, who collectively held 139,481,943 shares across 481 entities as of August 15, 2025. This significant institutional presence, with ownership reported at 102.82% in April and May 2025, suggests a strong influence from large investment firms, mutual funds, and pension funds on the company's strategic direction. While institutional investors lead, individual insiders also maintain stakes; as of May 2025, insider holdings represented 3.98% of the company's shares. Notably, co-founder Pascal Deschatelets held 1.52% as of January 2025, CEO Cedric Francois held 0.55%, and co-founder Alec Machiels held 0.5% as of December 2024. This blend of institutional and insider ownership often aligns management decisions with the long-term interests of major shareholders, fostering stable growth and robust governance practices. Understanding who owns Apellis is crucial for grasping its operational and strategic trajectory.

Apellis Pharmaceuticals: Ownership Snapshot

Apellis Pharmaceuticals' ownership is heavily concentrated among institutional investors, reflecting confidence in its growth potential.

• Institutional investors collectively own a significant majority of Apellis Pharmaceuticals stock.
• Key institutional stakeholders include Avoro Capital Advisors LLC and EcoR1 Capital, LLC.
• Insider ownership, though smaller, is held by founders and executives like Pascal Deschatelets and Cedric Francois.
• The high institutional ownership percentage can influence company strategy towards long-term value creation.
• For a deeper dive into the company's beginnings, explore the Brief History of Apellis Pharmaceuticals.

Apellis Pharmaceuticals PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Apellis Pharmaceuticals is instrumental in guiding the company's strategic direction and corporate governance. As of 2025, the board includes Gerald Chan as Chairman, alongside directors Sinclair Dunlop, Stephanie Monaghan O'Brien, Paul Fonteyne, Cedric Francois, Alec Machiels, Keli Walbert, and Craig Wheeler. Notably, co-founders Cedric Francois and Alec Machiels are board members, reflecting their continued involvement in the company's vision.

The board structure emphasizes independent oversight, with six out of seven directors classified as independent as of January 2025. Recent additions, Keli Walbert in January 2025 and Craig Wheeler in April 2025, have brought specialized expertise, particularly in biopharmaceutical commercial leadership and audit committee functions. While Apellis Pharmaceuticals operates under a standard one-share-one-vote structure typical for public companies, specific details regarding dual-class shares or unique voting rights are not publicly disclosed. The composition of the board, featuring co-founders alongside a strong contingent of independent directors and representatives of significant Apellis Pharmaceuticals investors, suggests a governance model that balances founder-led innovation with robust external accountability. Understanding the Target Market of Apellis Pharmaceuticals also provides context for the strategic decisions overseen by this board.

Board Composition and Governance

Apellis Pharmaceuticals' board is designed for effective oversight and strategic guidance. The majority of directors are independent, ensuring objective decision-making.

• Six of seven directors were independent as of January 2025.
• Recent appointments enhance biopharmaceutical and financial oversight.
• Co-founders maintain board representation, aligning with founding vision.
• Standard one-share-one-vote structure is presumed for Apellis Pharmaceuticals company structure.

Apellis Pharmaceuticals Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Apellis Pharmaceuticals has seen shifts in its operational and ownership landscape over the past few years. As of August 15, 2025, the company's stock was trading at $27.75 per share, marking a decrease from $38.57 on August 19, 2024.

Leadership changes and financial performance have been key developments. Adam Townsend, the former Chief Operating Officer, departed on February 21, 2025. David Acheson has since taken on the role of Executive Vice President of Commercial. Financially, Apellis reported revenues of $471.3 million in 2024, a substantial rise from $94.2 million in 2023, primarily due to Syfovre sales. However, the company recorded a net loss of $717.4 million for 2024. To bolster liquidity, Apellis entered a royalty purchase agreement in July 2025 with Sobi, potentially securing up to $300 million in exchange for 90% of its future ex-U.S. royalties for Aspaveli.

Leadership Transition

Adam Townsend left his COO position in February 2025. David Acheson has stepped into the role of Executive Vice President of Commercial.

Financial Performance Snapshot

2024 revenues reached $471.3 million, up from $94.2 million in 2023. The company reported a net loss of $717.4 million for 2024.

Liquidity Enhancement

A royalty purchase agreement in July 2025 provides potential access to $300 million. This agreement is for future ex-U.S. royalties related to Aspaveli.

Ownership Trends

Institutional investors hold a significant portion of Apellis's shares. Insider holdings saw a slight increase to 3.98% by May 2025.

Institutional investors are the dominant force in Apellis's ownership structure. While exact percentages can fluctuate and sometimes appear over 100% due to reporting methodologies that include short positions, this indicates substantial backing from large financial entities. Insider holdings, though smaller, showed a modest rise to 3.98% as of May 2025. Conversely, mutual fund holdings experienced a decrease to 41.37% in the same period. The company has indicated its cash reserves are expected to sustain operations until profitability is achieved, with some projections placing this around late 2026. Apellis continues to actively engage with the investment community, participating in conferences to discuss its performance and future strategy, aligning with its stated Mission, Vision & Core Values of Apellis Pharmaceuticals.

Apellis Pharmaceuticals Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔